BenchSci, a Canada-based company that deals with machine learning applications for novel medicine development, announced on Tuesday that it has named Luba Greenwood as its new director.
Greenwood has worked as an executive at Google Life Sciences (Verily) and as vice president of Global Business Development and Mergers & Acquisitions at Roche. She advises various multinational pharmaceutical, life science tool, tech, and cancer and research organisations, including the Dana Farber and the Wyss Center for Bio and Neuroengineering. She serves on various boards, including the Massachusetts Biotechnology Council, Brooklyn ImmunoTherapeutics, and Entrinsic Health. She has co-founded biotech and digital health firms in the immunotherapy, women's health, AI/ML, and microbiome spaces.
Liran Belenzon, BenchSci CEO, said, 'Luba's insights, network, and perspective are extremely valuable, and we are thrilled to welcome her to our board of directors at this exciting time. Her biotech, pharmaceutical, BD, and life sciences industry expertise will be instrumental as we scale our machine learning-based product portfolio to further enable scientists as they conduct life-saving R&D. We are honoured she agreed to join our board.'
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients